Psychedelics Investing NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression
Psychedelics Investing Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025
Psychedelics Investing Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
Psychedelics Investing Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA
Psychedelics Investing Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights
Psychedelics Investing Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025
Psychedelics Investing Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET
Psychedelics Investing Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
Psychedelics Investing Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
psychedelics investing Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
SAGA Metals Provides Update on Double Mer Uranium Project: A Well-Positioned Asset in North America as the Uranium Boom Accelerates
Spartan Metals Identifies High-Grade Silver-Rich CRD Target on Trend with Tungstonia Vein System at the Eagle Project
